Pharmacologic therapy of aphakic and pseudophakic cystoid macular edema. 1985 update.
Major advances in the pharmacologic therapy of aphakic cystoid macular edema (ACME) have not occurred since 1982. Topical nonsteroidal anti-inflammatory agents are still not commercially available for ocular therapy. Topical indomethacin remains the one agent which has been proven to be of prophylactic value for angiographic aphakic cystoid macular edema although other non-steroidal agents may also work. The therapeutic value of these compounds for established ACME remains uncertain. No prospective randomized prophylactic or therapeutic trials of either topical or systemic corticosteroids have been performed.
D000287:Administration, Topical; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001036:Aphakia, Postcataract; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use; D007910:Lenses, Intraocular / Q000009:adverse effects; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D011239:Prednisolone / Q000627:therapeutic use; D011897:Random Allocation; D013496:Suprofen / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D000893:Anti-Inflammatory Agents; D013496:Suprofen; D011239:Prednisolone; D007213:Indomethacin